These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19343887)

  • 21. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High patient satisfaction with the transdermal system].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):27. PubMed ID: 23646401
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
    Staskin DR; Rosenberg MT; Dahl NV; Polishuk PV; Zinner NR
    Int J Clin Pract; 2008 Jan; 62(1):27-38. PubMed ID: 17983434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
    Merino Salas S
    Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
    Pizzi LT; Talati A; Gemmen E; Dahl NV; Bunz TJ; Sand PK
    Pharmacoeconomics; 2009; 27(4):329-39. PubMed ID: 19485428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 27. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In brief: Oxytrol OTC.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):76. PubMed ID: 24662958
    [No Abstract]   [Full Text] [Related]  

  • 32. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.
    Hashim H; Malmberg L; Graugaard-Jensen C; Abrams P
    Neurourol Urodyn; 2009; 28(1):40-6. PubMed ID: 18726947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
    Wong C; Duggan P
    J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application drying time for oxybutynin chloride topical gel.
    Newman DK; Olsen SM; Dahl NV
    Urol Nurs; 2012; 32(5):265-9. PubMed ID: 23472531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of overactive bladder on women in the United States: results of a national survey.
    Dmochowski RR; Newman DK
    Curr Med Res Opin; 2007 Jan; 23(1):65-76. PubMed ID: 17257467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
    Gish P; Mosholder AD; Truffa M; Johann-Liang R
    J Pediatr; 2009 Sep; 155(3):432-4. PubMed ID: 19732583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overactive bladder syndrome in older people.
    Wagg AS; Cardozo L; Chapple C; De Ridder D; Kelleher C; Kirby M; Milsom I; Vierhout M
    BJU Int; 2007 Mar; 99(3):502-9. PubMed ID: 17407511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of symptoms severity in patients with overactive bladder].
    Al'-Shukri SKh; Kuz'min IV
    Urologiia; 2008; (6):37-40. PubMed ID: 19248597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.